Ro 07-1902
Ro 07-1902 is a potent antitumor synergist. Ro 07-1902 enhances the antitumor effects of CCNU (HY-13669), Chlorambucil (HY-13593) and Cyclophosphamide (HY-17420). Ro 07-1902 exhibits no single-agent cytotoxicity and does not delay tumor growth. Ro 07-1902 can be used in research related to various cancers.
For research use only. We do not sell to patients.
- CAS No.: 68160-71-4
- Formula: C9H13N3O4
- Molecular Weight:227.22
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Ro 07-1902 has an octanol/water partition coefficient of 2.5 at pH 7.4, a value associated with potent enhancement of CCNU's anti-tumour effect in the KHT fibrosarcoma model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ro 07-1902 (1.0-2.0 μmol/g; i.p.; single administration) acts as a potent enhancer of cyclophosphamide cytotoxicity in C57Bl/Cbi mice bearing Lewis lung carcinoma[2].
Ro 07-1902 (1 mmol/kg; i.p.; single administration) enhances the tumor growth delay effect of chlorambucil on RIF-1 mouse sarcoma[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C3H/He (both sexes, 12-16 weeks old, 20-30 g, KHT fibrosarcoma grown intramuscularly in hind limb)[1]
-
Dosage:0.1 mmol/kg; 0.9 mmol/kg; 2.5 mmol/kg; 3.0 mmol/kg; 4.0 mmol/kg
-
Administration:i.p.; single dose 30 min before CCNU
-
Result:Exhibited Activity Index values of 3.1, 2.4, 4.1, and 3.3 at 2.5 mmol/kg, being 2.4-4.1 times more active than MISO at enhancing CCNU's anti-tumour effect.
Increased tumour growth delay for 10 mg/kg CCNU to exceed the growth delay caused by 20 mg/kg CCNU alone at 2.5 mmol/kg, resulting in a dose-modifying factor greater than 2.
Was considerably more active than MISO at low doses (0.1-0.9 mmol/kg), and was the most active agent evaluated at high doses, producing tumour growth delays of up to 9 days when combined with 10 mg/kg CCNU.
Did not alter tumour response when mouse body temperature was maintained.
-
Animal Model:C57Bl/Cbi (female, 2-3 months old, subcutaneous implantation of Lewis lung carcinoma cells)[2]
-
Dosage:1.0 μmol/g; 2.0 μmol/g
-
Administration:i.p.; single dose; 20 minutes before cyclophosphamide
-
Result:Reduced the surviving fraction per gram of tumor relative to cyclophosphamide alone.
-
Animal Model:C3H/He (male and female, 12-16 weeks old, 20-28 g, intramuscularly grown RIF-1 sarcoma model)[3]
-
Dosage:1 mmol/kg
-
Administration:i.p.; single dose; 30 minutes prior to chlorambucil
-
Result:Produced a tumor growth delay of 8.4 days when combined with 7.5 mg/kg chlorambucil.
Produced a tumor growth delay of 13.9 days when combined with 7.5 mg/kg chlorambucil.
Was at least as effective as 2.5 mmoles/kg misonidazole in enhancing chlorambucil's antitumor effect.
Chemical Information
-
CAS No. 68160-71-4
-
Molecular Weight 227.22
-
Formula C9H13N3O4
-
SMILES
OC(CN1C=CN=C1[N+]([O-])=O)CO/C=C/C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1].
Workman P, Twentyman PR. Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. Br J Cancer. 1982;46(2):249–259.
[Content Brief]
[2].
Chaplin DJ, et al. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles. Int J Radiat Oncol Biol Phys. 1984;10(9):1647–1651.
[Content Brief]
[3].
Twentyman PR, Workman P. The effect of radiosensitizer pretreatment on the response of the RIF-1 mouse sarcoma to cytotoxic drugs. Int J Radiat Oncol Biol Phys. 1982;8(3–4):611–613.
[Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)